## Nasdaq Regulation



Arnold Golub Vice President Deputy General Counsel

**By Electronic Mail** 

February 10, 2021

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

**Division of Corporation Finance:** 

This is to certify that on February 8, 2021 The Nasdaq Stock Market LLC (the "Exchange") received from GT Biopharma, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

Common stock, par value \$0.001 per share

We further certify that the security described above has been approved by the Exchange for listing and registration.

We understand that the Registrant is seeking immediate acceleration of the effective date of registration, and we hereby join in such request.

Sincerely,

all Ishh